Drug Hunter

"Our teams have to extract structures from patents all the time." That's what a portfolio strategy leader at a top 50 pharma told us. “We need to benchmark the performance of patented compounds in different animal models against our own lead compounds. There is no platform where this can be done as easily as Drug Hunter." Notable Patent Structures are now live in Drug Hunter's Curated Patents feed. Now you can quickly scan each week’s notable new patent filings to stay current on what the industry is working on. Already a Drug Hunter member? Log in and navigate to Patents. Think this tool would help your team? Read more about Drug Hunter’s Curated Patents here: https://lnkd.in/gP8yXhY8/?utm_campaign=Boost_Post_BrandAwareness_Oct23,2026&utm_source=linkedin&utm_medium=paid&utm_id=1236676166&hsa_acc=510103803&hsa_cam=1236676166&hsa_grp=917438846&hsa_ad=1658351986&hsa_net=linkedin&hsa_ver=3/ What's the slowest part of patent review for your team?

Reminder: Live Flash Talk this Thursday👇 𝗟𝗲𝘃𝗲𝗿𝗮𝗴𝗶𝗻𝗴 𝗣𝗹𝗮𝘁𝗳𝗼𝗿𝗺 𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻 𝘁𝗼 𝗧𝗮𝗰𝗸𝗹𝗲 𝗧𝗼𝘂𝗴𝗵 𝗧𝗮𝗿𝗴𝗲𝘁𝘀 🗓️ Thursday, Oct. 22th ⏰ 8 AM PT | 11 AM ET | 5 PM CET Drug discovery is increasingly focused on biological targets once considered undruggable. In this difficult-to-drug space, success depends on understanding how the target should be modulated, identifying molecules capable of delivering the desired mechanism, and rapidly establishing confidence in their activity. In this Flash Talk, Andrea Weston, Head of Discovery Biology and Pharmacology at Pfizer, will explore how the thoughtful integration of platform technologies can improve the probability of success against challenging targets. She will highlight how the right protein reagents and cellular models can be critical to successful lead identification, and how defining the desired mechanism of action before screening can better position programs for success. Andrea will also examine current hit-finding strategies and emerging approaches for elucidating small-molecule MoAs, sharing how these advances are collectively expanding the boundaries of druggability and creating new opportunities to discover transformative medicines. 🔗 Register now to learn more about recent advances in platform technologies and their applications towards difficult-to-drug targets: https://lnkd.in/gqu4pPBZ #DrugDiscovery #MedicinalChemistry #SmallMolecule #HitFinding #LeadDiscovery

Notable Patent Structures are now live in Drug Hunter's Curated Patents feed! Who has time to open every new patent filing each week? Now, the Curated Patents feed allows you to quickly scan each week’s notable new patent filings to stay current on what the industry is working on. You can now: • 𝗦𝗰𝗮𝗻 𝗻𝗲𝘄 𝗿𝗲𝗹𝗲𝗮𝘀𝗲𝘀 𝗯𝘆 𝘀𝘁𝗿𝘂𝗰𝘁𝘂𝗿𝗲. See example structures alongside company, target, relevant therapeutic area, and individual patent data annotations. • 𝗦𝗸𝗶𝗽 𝗠𝗮𝗿𝗸𝘂𝘀𝗵 𝗲𝘆𝗲𝘀𝗼𝗿𝗲𝘀. See specific example compounds validated by Ph.D. scientists to get a quick sense of the chemical matter. • 𝗦𝘁𝗮𝘆 𝗰𝘂𝗿𝗿𝗲𝗻𝘁 𝘄𝗶𝘁𝗵 𝘁𝗵𝗲 𝗯𝗿𝗼𝗮𝗱𝗲𝗿 𝗶𝗻𝗱𝘂𝘀𝘁𝗿𝘆. We triage filings so that you can tune out the noise and quickly understand disclosures from across the industry outside of your main focus area. • 𝗚𝗼 𝗱𝗲𝗲𝗽𝗲𝗿 𝘄𝗶𝘁𝗵 𝗠𝗼𝗹𝗲𝗰𝘂𝗹𝗲 𝗦𝗲𝗮𝗿𝗰𝗵. Copy/paste any SMILES into Molecule Search and edit it to find related clinical compounds, FDA approvals, and disclosures. Already a Drug Hunter member? Log in and navigate to Patents! Think this tool would help your team? Read more about Drug Hunter’s Curated Patents here: https://lnkd.in/eSNWZv_2/?utm_campaign=Boost_Post_BrandAwareness_Oct16,2026&utm_source=linkedin&utm_medium=paid&utm_id=1231927616&hsa_acc=510103803&hsa_cam=1231927616&hsa_grp=914217416&hsa_ad=1647267766&hsa_net=linkedin&hsa_ver=3 #DrugDiscovery

Reminder: Live Flash Talk this Thursday👇 The Sulfoximine Paradox: Understanding the Unique Physicochemical Properties of Secondary Sulfonamide Bioisosteres 🗓️ Thursday, Oct. 15th ⏰ 8 AM PT | 11 AM ET | 5 PM CET Secondary sulfonamides occur in approved medicines at a far lower rate than in screening libraries. This highlights the potential for isosteres that could achieve similar interactions but with distinct properties. In this Thursday's Flash Talk, Michael Shultz, Director in Global Discovery Chemistry at Novartis, will discuss the unique properties of sulfoximines as secondary sulfonamide isosteres. In particular, he will present the observed differences in properties such as aqueous solubility and plasma protein binding, using MMP analysis, highlighting where values like predicted logP or fu fall short. 🔗 Register now to learn more about the sulfoximine paradox: https://lnkd.in/eijP9QgP #DrugDiscovery #DrugDevelopment

In this Flash Talk Georg Winter shared how TPD can serve as a tool to both disrupt and activate signaling pathways. Despite the utilization of induced proximity strategies in clinical candidates and approved drugs, details on MoA remain unclear. Georg presented how his lab and Nicolas Thomä's worked to elucidate the MoA of SERDs like fulvestrant. He demonstrated that SERD binding induces ERα SUMOylation followed by ubiquitination and degradation mediated by STUbLs. Similar SUMOylation and immobilization mechanism were actually identified for several non-ER targeting clinical candidates. While heterobifunctional degraders are aimed at a loss of function, Georg also presented the application of heterobifunctional molecules to reprogram rather than eliminate a target. In particular, he discussed how the heterobifunctional ligand TRIP-1 could induce ternary complex formation between SMARCA4 and BCL6 to promote the transcription of pro-apoptotic genes. In vitro data indicates that this approach can provide superior induction of apoptosis and cell death relative to BCL6 inhibition or degradation. If you want to learn more about how a detailed MoA understanding can inspire the next generation of induced proximity drugs, watch the full Flash Talk on our YouTube channel: https://lnkd.in/emRDThtC/?utm_campaign=Boost_Post_VideoViews_Oct12,2026&utm_source=linkedin&utm_medium=paid&utm_id=1231006776&hsa_acc=510103803&hsa_cam=1231006776&hsa_grp=912301956&hsa_ad=1641154746&hsa_net=linkedin&hsa_ver=3

Leveraging Platform Innovation to Tackle Tough Targets https://lnkd.in/eVU5xFCa Thursday, October 22nd, 2026 8 AM PT | 11 AM ET | 5 PM CET Drug discovery is increasingly focused on biological targets once considered undruggable. In this difficult-to-drug space, success depends on understanding how the target should be modulated, identifying molecules capable of delivering the desired mechanism, and rapidly establishing confidence in their activity. In this Flash Talk, Andrea Weston, Head of Discovery Biology and Pharmacology at Pfizer, will explore how the thoughtful integration of platform technologies can improve the probability of success against challenging targets. She will highlight how the right protein reagents and cellular models can be critical to successful lead identification, and how defining the desired mechanism of action before screening can better position programs for success. Andrea will also examine current hit-finding strategies and emerging approaches for elucidating small-molecule MoAs, sharing how these advances are collectively expanding the boundaries of druggability and creating new opportunities to discover transformative medicines. Register now to learn more about recent advances in platform technologies and their applications towards difficult-to-drug targets: https://lnkd.in/ejdut4Jg